{
    "Trade/Device Name(s)": [
        "Direct Bilirubin"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K152343",
    "Predicate Device Reference 510(k) Number(s)": [
        "K053132"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JFM"
    ],
    "Summary Letter Date": "January 04, 2016",
    "Summary Letter Received Date": "January 06, 2016",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin (total or direct) test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Direct Bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (Lithium Heparin)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "RX Daytona Plus"
    ],
    "Method(s)/Technology(ies)": [
        "Vanadate Oxidation Method",
        "Photometric endpoint measurement"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Direct Bilirubin test system using vanadate oxidation method for quantitative determination of direct bilirubin in serum and plasma",
    "Indications for Use Summary": "Quantitative in vitro determination of direct bilirubin in serum and plasma for use in diagnosis and treatment of liver, hemolytic, hematological, and metabolic disorders including hepatitis and gall bladder block",
    "fda_folder": "Clinical Chemistry"
}